Compare BridgeBio Pharma Inc (BBIO) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard High Dividend Yield ETF — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while Vanguard High Dividend Yield ETF trades at $160.18. Which is the better fit depends on your goals.
| BBIO | VYM | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $90.17 | $161.17 |
52-Week Low | $44.81 | $132.90 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
VYM trades at $160.86, down slightly by 0.12% today, with a bullish technical outlook supported by moving averages. The ETF maintains strong investor interest as a dividend income vehicle with $78.33 billion in assets and 618 holdings. Recent news highlights its role in retirement portfolios for tax-efficient income generation, though some articles question whether alternative funds offer better yields or performance.
The outlook remains positive for income-focused investors seeking broad diversification and low costs. Key risks include interest rate sensitivity and potential dividend sustainability during market downturns. Analyst sentiment favors VYM for long-term dividend growth despite current yield comparisons with competing ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
